#1 Clinical Trials Search in Europe

Clioquinol

Clioquinol, a versatile drug, is currently being studied in various clinical trials for its potential benefits in treating different medical conditions. These trials are exploring its effectiveness in managing drug-resistant childhood epilepsy, hematological malignancies, and dermatitis eczematous. Researchers are investigating the drug’s safety, efficacy, and optimal dosing strategies to determine its potential as a treatment option for these diverse health issues.

Table of Contents

What is Clioquinol?

Clioquinol is a medication that is currently being studied for its potential to treat various medical conditions. It’s important to note that this drug is still in the research phase, which means it’s not yet widely available for general use. Scientists are conducting clinical trials to better understand how clioquinol works and determine its effectiveness in treating different diseases.[1][2][3]

Potential Uses of Clioquinol

Research is ongoing to explore the potential benefits of clioquinol in treating several conditions:

  • Drug-resistant childhood epilepsy: A type of epilepsy that doesn’t respond well to standard treatments[1]
  • Blood cancers: Including acute myeloid leukemia, acute lymphocytic leukemia, chronic lymphocytic leukemia, myelodysplasia, non-Hodgkin’s lymphoma, Hodgkin’s lymphoma, and multiple myeloma[2]
  • Skin conditions: Such as acute and sub-acute eczematous dermatitis (a type of skin inflammation)[3]

Clioquinol in Childhood Epilepsy

One clinical trial is investigating the use of clioquinol as an additional treatment for children with drug-resistant epilepsy. This type of epilepsy is particularly challenging because it doesn’t respond well to standard anti-seizure medications. The study aims to determine if adding clioquinol to a child’s existing medication regimen can help reduce the frequency and severity of seizures.[1]

Key points about this study include:

  • It focuses on adolescents with drug-resistant epilepsy
  • Clioquinol is given in addition to the patient’s regular anti-epileptic medications
  • The treatment period lasts up to 8 weeks
  • Researchers will measure the reduction in seizure frequency and the number of patients who respond positively to the treatment
  • The study will also assess the impact on seizure severity, overall quality of life, and potential side effects

Clioquinol in Blood Cancers

Another clinical trial is exploring the potential of clioquinol in treating various types of blood cancers that have not responded to other treatments or have come back after previous treatment. This study aims to determine the safe dosage of clioquinol and understand how it affects cancer cells.[2]

The blood cancers being studied include:

  • Acute Myeloid Leukemia (AML): A cancer of the blood and bone marrow
  • Acute Lymphocytic Leukemia (ALL): A type of cancer in which the bone marrow makes too many lymphocytes (a type of white blood cell)
  • Chronic Lymphocytic Leukemia (CLL): A type of cancer that affects the blood and bone marrow
  • Myelodysplasia: A group of disorders in which blood cells don’t mature properly
  • Non-Hodgkin’s Lymphoma: A cancer that starts in white blood cells called lymphocytes
  • Hodgkin’s Lymphoma: A cancer of the lymphatic system
  • Multiple Myeloma: A cancer of plasma cells, a type of white blood cell

Clioquinol in Skin Conditions

Clioquinol is also being studied as part of a combination treatment for skin conditions, specifically acute and sub-acute eczematous dermatitis. This is a type of skin inflammation that causes itching and visible skin lesions, which can significantly impact a person’s quality of life.[3]

In this study, clioquinol is combined with other medications:

  • One group receives a cream containing polymyxin B sulphate, prednisolone, benzocaine, and clioquinol
  • Another group receives a cream containing betamethasone, gentamicin, tolnaftate, and clioquinol

The goal is to compare the effectiveness of these two combinations in reducing the symptoms and severity of eczematous dermatitis.

How is Clioquinol Administered?

The method of administering clioquinol varies depending on the condition being treated:

  • For epilepsy: It’s given orally as a liquid suspension[1]
  • For blood cancers: It’s taken orally, with the dosage gradually increased over time[2]
  • For skin conditions: It’s applied topically as part of a cream, usually three times a day[3]

Potential Side Effects and Safety Concerns

As clioquinol is still being researched, its full range of potential side effects is not yet known. The clinical trials are designed to monitor for any adverse effects and assess the overall safety of the drug. Patients participating in these studies are closely monitored for any unexpected reactions.[1][2][3]

It’s important to remember that clioquinol is not currently approved for general use. If you’re interested in learning more about this medication or participating in a clinical trial, you should discuss this with your healthcare provider. They can provide more information and help determine if you might be eligible for any ongoing studies.

Trial Focus Condition Clioquinol Use Key Outcomes Measured
Childhood Epilepsy Drug-resistant epilepsy Add-on to existing medications Seizure frequency reduction, safety, quality of life
Hematological Malignancies Various blood cancers Oral administration with dose escalation Maximum tolerated dose, pharmacokinetics, response rate
Skin Conditions Dermatitis eczematous Part of a combination topical cream Reduction of signs and symptoms, adverse events

FAQ

  • What is Clioquinol being studied for in clinical trials? Clioquinol is being studied for its potential benefits in treating drug-resistant childhood epilepsy, various hematological malignancies (such as leukemia and lymphoma), and dermatitis eczematous (a type of skin condition).
  • How is Clioquinol being used in the epilepsy trial? In the epilepsy trial, Clioquinol is being used as an add-on treatment to existing anti-seizure medications. Patients are given a low dose (1mg/kg/day) for 2 weeks, followed by a higher dose (4mg/kg/day) for 6 weeks.
  • What is the main goal of the hematological malignancy trial? The main goal of the hematological malignancy trial is to evaluate the dose-limiting toxicity, maximum tolerated dose, and recommended phase II dose of Clioquinol in patients with relapsed or refractory blood cancers.
  • How is Clioquinol being used in the dermatitis eczematous trial? In the dermatitis eczematous trial, Clioquinol is part of a combination cream that includes polymyxin B sulphate, prednisolone, and benzocaine. This cream is applied to skin lesions three times a day and compared to another combination cream.
  • What are some of the outcomes being measured in these trials? The trials are measuring various outcomes, including seizure frequency reduction in epilepsy, drug safety and tolerability, pharmacokinetics (how the drug moves through the body), and improvement of signs and symptoms in skin conditions.

Ongoing Clinical Trials on Clioquinol

  • Study on Clioquinol for Reducing Seizures in Patients with Drug-Resistant Epilepsy

    Recruiting

    2 1 1
    Investigated diseases:
    Investigated drugs:
    Belgium

Glossary

  • Clioquinol: A drug being studied for its potential benefits in treating various medical conditions, including epilepsy, blood cancers, and skin disorders.
  • Drug-resistant epilepsy: A form of epilepsy where seizures are not well-controlled with standard anti-epileptic medications.
  • Hematological malignancy: Cancers that affect the blood, bone marrow, and lymph nodes, such as leukemia and lymphoma.
  • Dermatitis eczematous: A skin condition characterized by itchy, inflamed, and irritated skin.
  • Add-on treatment: A medication or therapy given in addition to the primary treatment to enhance its effectiveness.
  • Pharmacokinetics: The study of how a drug moves through the body, including its absorption, distribution, metabolism, and excretion.
  • Maximum tolerated dose (MTD): The highest dose of a drug that can be given without causing unacceptable side effects.
  • Phase 1 study: An early stage clinical trial that focuses on testing a drug's safety and determining the appropriate dosage.
  • Phase 2 study: A clinical trial that further evaluates a drug's effectiveness and safety in a larger group of patients.
  • Responder rate: The percentage of patients who show a significant positive response to a treatment, often defined as a 50% or greater reduction in symptoms.
  • Quality of Life (QoL): A measure of a person's overall well-being and ability to function in daily life.
  • Adverse events: Unexpected or harmful reactions that occur during a clinical trial or treatment.

References

  1. https://clinicaltrials.gov/study/NCT05727943
  2. https://clinicaltrials.gov/study/NCT00963495
  3. https://clinicaltrials.gov/study/NCT01429701